Cantor Fitzgerald Research Analysts Lift Earnings Estimates for NewLink Genetics Co. (NLNK)

NewLink Genetics Co. (NASDAQ:NLNK) – Equities researchers at Cantor Fitzgerald increased their FY2018 earnings per share (EPS) estimates for NewLink Genetics in a research note issued to investors on Tuesday, May 22nd. Cantor Fitzgerald analyst M. Goldstein now forecasts that the biotechnology company will earn ($1.98) per share for the year, up from their previous forecast of ($2.14). Cantor Fitzgerald has a “Hold” rating and a $7.00 price target on the stock. Cantor Fitzgerald also issued estimates for NewLink Genetics’ FY2019 earnings at ($1.42) EPS.

Several other brokerages have also issued reports on NLNK. Bank of America dropped their price target on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, March 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $21.00 price target (down from $25.00) on shares of NewLink Genetics in a research note on Friday, March 2nd. ValuEngine lowered NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Saturday, May 5th. Finally, Robert W. Baird lowered NewLink Genetics from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $22.00 to $5.00 in a research note on Monday, April 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $10.50.

Shares of NewLink Genetics opened at $5.40 on Thursday, according to Marketbeat. NewLink Genetics has a 52-week low of $3.75 and a 52-week high of $19.30. The company has a market capitalization of $198.09 million, a price-to-earnings ratio of -2.35 and a beta of 1.25.

NewLink Genetics (NASDAQ:NLNK) last issued its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. NewLink Genetics had a negative return on equity of 55.64% and a negative net margin of 193.44%. The firm had revenue of $9.90 million for the quarter, compared to analyst estimates of $5.78 million.

Several large investors have recently modified their holdings of NLNK. Creative Planning acquired a new position in shares of NewLink Genetics during the fourth quarter worth approximately $152,000. Schwab Charles Investment Management Inc. raised its position in shares of NewLink Genetics by 22.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 100,944 shares of the biotechnology company’s stock worth $819,000 after purchasing an additional 18,712 shares during the period. Acadian Asset Management LLC raised its position in shares of NewLink Genetics by 241.6% during the fourth quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 13,770 shares during the period. Swiss National Bank raised its position in shares of NewLink Genetics by 26.6% during the fourth quarter. Swiss National Bank now owns 45,200 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 9,500 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of NewLink Genetics by 7.9% during the fourth quarter. Wells Fargo & Company MN now owns 373,682 shares of the biotechnology company’s stock worth $3,031,000 after purchasing an additional 27,242 shares during the period. 53.04% of the stock is currently owned by institutional investors.

NewLink Genetics Company Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply